Confidentiality Orders and Public Interest in Drug and Medical Device Litigation
Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. Howeve...
Gespeichert in:
Veröffentlicht in: | Archives of internal medicine (1960) 2020-02, Vol.180 (2), p.292-299 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 299 |
---|---|
container_issue | 2 |
container_start_page | 292 |
container_title | Archives of internal medicine (1960) |
container_volume | 180 |
creator | Egilman, Alexander C Kesselheim, Aaron S Krumholz, Harlan M Ross, Joseph S Kim, Jeanie Kapczynski, Amy |
description | Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases. |
doi_str_mv | 10.1001/jamainternmed.2019.5161 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2309807409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2753427</ama_id><sourcerecordid>2309807409</sourcerecordid><originalsourceid>FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</originalsourceid><addsrcrecordid>eNpdkEtLAzEUhYMoWLR_wI0BN26m5jGTTJbS-ihU2oWuQ5pHSZlmajIj9N-bsVLQm8W9cL9zuDkA3GI0wQjhh63aKR86G8POmglBWEwqzPAZGBHM6oJhXJ6fZsQuwTilLcpVI1RSOgKraRucNzZ0XjW-O8BlNDYmqIKBq37deA3ng79NHfQBzmK_-dm9WeO1auDMfnlt4cJ3fqM634ZrcOFUk-z4t1-Bj-en9-lrsVi-zKePi0JRyruiqokzjlSlE_m5ShNdGl6JyhJOeEVRzZymhjGK1pQpTLRxQtC1M0pYnYErcH_03cf2s8_nyZ1P2jaNCrbtkyQUiRrxEomM3v1Dt20fQ74uU4zXZUnwYMiPlI5tStE6uY9-p-JBYiSHsOWfsOUQthzCzsqbozLvT6LhEyXh9BuPKX5A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2367844215</pqid></control><display><type>article</type><title>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</title><source>American Medical Association Journals</source><creator>Egilman, Alexander C ; Kesselheim, Aaron S ; Krumholz, Harlan M ; Ross, Joseph S ; Kim, Jeanie ; Kapczynski, Amy</creator><creatorcontrib>Egilman, Alexander C ; Kesselheim, Aaron S ; Krumholz, Harlan M ; Ross, Joseph S ; Kim, Jeanie ; Kapczynski, Amy</creatorcontrib><description>Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases.</description><identifier>ISSN: 2168-6106</identifier><identifier>EISSN: 2168-6114</identifier><identifier>DOI: 10.1001/jamainternmed.2019.5161</identifier><language>eng</language><publisher>Chicago: American Medical Association</publisher><subject>Confidentiality ; Litigation ; Pharmaceutical industry ; Public interest</subject><ispartof>Archives of internal medicine (1960), 2020-02, Vol.180 (2), p.292-299</ispartof><rights>Copyright American Medical Association Feb 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</citedby><cites>FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamainternalmedicine/articlepdf/10.1001/jamainternmed.2019.5161$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2019.5161$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76231,76234</link.rule.ids></links><search><creatorcontrib>Egilman, Alexander C</creatorcontrib><creatorcontrib>Kesselheim, Aaron S</creatorcontrib><creatorcontrib>Krumholz, Harlan M</creatorcontrib><creatorcontrib>Ross, Joseph S</creatorcontrib><creatorcontrib>Kim, Jeanie</creatorcontrib><creatorcontrib>Kapczynski, Amy</creatorcontrib><title>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</title><title>Archives of internal medicine (1960)</title><description>Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases.</description><subject>Confidentiality</subject><subject>Litigation</subject><subject>Pharmaceutical industry</subject><subject>Public interest</subject><issn>2168-6106</issn><issn>2168-6114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkEtLAzEUhYMoWLR_wI0BN26m5jGTTJbS-ihU2oWuQ5pHSZlmajIj9N-bsVLQm8W9cL9zuDkA3GI0wQjhh63aKR86G8POmglBWEwqzPAZGBHM6oJhXJ6fZsQuwTilLcpVI1RSOgKraRucNzZ0XjW-O8BlNDYmqIKBq37deA3ng79NHfQBzmK_-dm9WeO1auDMfnlt4cJ3fqM634ZrcOFUk-z4t1-Bj-en9-lrsVi-zKePi0JRyruiqokzjlSlE_m5ShNdGl6JyhJOeEVRzZymhjGK1pQpTLRxQtC1M0pYnYErcH_03cf2s8_nyZ1P2jaNCrbtkyQUiRrxEomM3v1Dt20fQ74uU4zXZUnwYMiPlI5tStE6uY9-p-JBYiSHsOWfsOUQthzCzsqbozLvT6LhEyXh9BuPKX5A</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Egilman, Alexander C</creator><creator>Kesselheim, Aaron S</creator><creator>Krumholz, Harlan M</creator><creator>Ross, Joseph S</creator><creator>Kim, Jeanie</creator><creator>Kapczynski, Amy</creator><general>American Medical Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20200201</creationdate><title>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</title><author>Egilman, Alexander C ; Kesselheim, Aaron S ; Krumholz, Harlan M ; Ross, Joseph S ; Kim, Jeanie ; Kapczynski, Amy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a337t-582fdf254f9f9ff5c2c4d7595e272753086fc3d6630b36a12cdf993bfda9ec753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Confidentiality</topic><topic>Litigation</topic><topic>Pharmaceutical industry</topic><topic>Public interest</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Egilman, Alexander C</creatorcontrib><creatorcontrib>Kesselheim, Aaron S</creatorcontrib><creatorcontrib>Krumholz, Harlan M</creatorcontrib><creatorcontrib>Ross, Joseph S</creatorcontrib><creatorcontrib>Kim, Jeanie</creatorcontrib><creatorcontrib>Kapczynski, Amy</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of internal medicine (1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Egilman, Alexander C</au><au>Kesselheim, Aaron S</au><au>Krumholz, Harlan M</au><au>Ross, Joseph S</au><au>Kim, Jeanie</au><au>Kapczynski, Amy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Confidentiality Orders and Public Interest in Drug and Medical Device Litigation</atitle><jtitle>Archives of internal medicine (1960)</jtitle><date>2020-02-01</date><risdate>2020</risdate><volume>180</volume><issue>2</issue><spage>292</spage><epage>299</epage><pages>292-299</pages><issn>2168-6106</issn><eissn>2168-6114</eissn><abstract>Litigation involving drug and medical device manufacturers has the potential to reveal important information about product efficacy and safety as well as company marketing. Prevailing legal standards recognize the public’s interest in having access to certain types of information in lawsuits. However, in practice, courts and litigants commonly use overly broad or unwarranted confidentiality orders, which can prevent the public from accessing important public health information that emerges during litigation. This Special Communication reviews the rules governing confidentiality orders and discusses the tension between these rules and prevailing legal practices relating to court secrecy in medical product litigation, including competing interests among manufacturers, plaintiffs, and courts. Using examples of successful efforts to challenge confidentiality orders, we describe how these prevailing legal practices can undermine access to information by patients, clinicians, and the US Food and Drug Administration and also obscure patterns of injury and disease associated with the drugs and medical devices at issue. We then discuss several ways to advance access to information important to public health that emerges during litigation, focusing particularly on the role of medical experts engaged in cases.</abstract><cop>Chicago</cop><pub>American Medical Association</pub><doi>10.1001/jamainternmed.2019.5161</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-6106 |
ispartof | Archives of internal medicine (1960), 2020-02, Vol.180 (2), p.292-299 |
issn | 2168-6106 2168-6114 |
language | eng |
recordid | cdi_proquest_miscellaneous_2309807409 |
source | American Medical Association Journals |
subjects | Confidentiality Litigation Pharmaceutical industry Public interest |
title | Confidentiality Orders and Public Interest in Drug and Medical Device Litigation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T17%3A05%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Confidentiality%20Orders%20and%20Public%20Interest%20in%20Drug%20and%20Medical%20Device%20Litigation&rft.jtitle=Archives%20of%20internal%20medicine%20(1960)&rft.au=Egilman,%20Alexander%20C&rft.date=2020-02-01&rft.volume=180&rft.issue=2&rft.spage=292&rft.epage=299&rft.pages=292-299&rft.issn=2168-6106&rft.eissn=2168-6114&rft_id=info:doi/10.1001/jamainternmed.2019.5161&rft_dat=%3Cproquest_cross%3E2309807409%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2367844215&rft_id=info:pmid/&rft_ama_id=2753427&rfr_iscdi=true |